October 2025 proved to be a significant month for the oncology landscape, marked by a wave of key regulatory decisions from the US FDA. This period saw important full and accelerated drug approvals ...
Dr. Mary Maluccio discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 ...
The AMPLIFY study [NCT03836261] did not include patients with del (17p), so that doublet is not relevant. The study that used ...
Specifically, in the PRRT-naive cohort, the ORR reached 60%, while 34.1% of patients showed stable disease. Combining these ...
CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...
An exosome-based treatment of glioblastoma multiforme (GBM) has received orphan drug designation from the FDA. 1 Exousia AI, ...
Rosen's excitement about AI stems from the ability to move beyond population health theories to deliver truly individualized ...
Panelists discuss current frontline therapeutic strategies for advanced melanoma, highlighting the rationale and evolution of ...
Jaume Capdevila, MD, Vall d'Hebron Hospital, discusses the final analysis of the phase 3 COMPETE trial (NCT03049189). Data ...
A panelist discusses how data from the DeLLphi-304 trial position tarlatamab as a potential new standard for relapsed ...
Molecular analysis identified ABC and GCB subtypes, with the ABC subtype benefiting more from the new regimen. The ...
A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback